Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities (2021 - 2023)

Historic Total Non-Current Liabilities for Arcturus Therapeutics Holdings (ARCT) over the last 3 years, with Q4 2023 value amounting to $150.4 million.

  • Arcturus Therapeutics Holdings' Total Non-Current Liabilities fell 1516.27% to $150.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $150.4 million, marking a year-over-year decrease of 1516.27%. This contributed to the annual value of $150.4 million for FY2023, which is 1516.27% down from last year.
  • Arcturus Therapeutics Holdings' Total Non-Current Liabilities amounted to $150.4 million in Q4 2023, which was down 1516.27% from $176.6 million recorded in Q3 2023.
  • Arcturus Therapeutics Holdings' 5-year Total Non-Current Liabilities high stood at $177.3 million for Q4 2022, and its period low was $128.5 million during Q1 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $144.3 million (2022), whereas its average is $153.0 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Total Non-Current Liabilities plummeted by 1708.58% in 2022 and then skyrocketed by 2240.58% in 2023.
  • Over the past 3 years, Arcturus Therapeutics Holdings' Total Non-Current Liabilities (Quarter) stood at $174.0 million in 2021, then grew by 1.87% to $177.3 million in 2022, then decreased by 15.16% to $150.4 million in 2023.
  • Its last three reported values are $150.4 million in Q4 2023, $176.6 million for Q3 2023, and $144.2 million during Q2 2023.